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ABSTRACT
Going for Gold: Point of Care Bio-Diagnostics and
Gold Nanoparticles Treating Disease
Trevor M. Godfrey
Department of Chemistry and Biochemistry, BYU
Master of Science
Correct diagnosis of disease is essential in the effort to save and improve lives. Point of
care (POC) diagnostics are in-vitro tests that assist in patient diagnosis and can be used at the
location of patient care. POC diagnostics are easy to use and provide near-instant readouts allowing
medical providers and patients to make rapid decisions about treatment. Increased access to POC
testing is especially beneficial to low-income and low resource areas that cannot afford expensive
lab testing. The World Health Organization (WHO) has outlined at least 113 diseases for which
POC diagnostics are needed. Because of this, developing effective, efficient, and economical
methods for creating new POC tests is essential. Work in section one of this thesis describes
strategies by which new POC bio-diagnostics can be created. The use of oxidized cellulose as a
vector for antibody immobilization was explored in several cellulose-based materials to provide
quick, economical tests while still obtaining effective limits of detection when used to detect the
pregnancy hormone Human Chorionic Gonadotropin (HCG) in a proof of concept study. The
majority of these tests could detect as low as 100 ng/mL of HCG well below the clinical level
necessary for detection at 2400 ng/mL. The use of a hand-powered syringe-based POC named the
fast flow immunoassay (FFI) was tested for its ability to increase observable signal in a sandwich
immunoassay by passing the sample through the test filter multiple times. 10 passes through the
filter resulted in a signal approximately 17x more intense than a 1-hour dot-blot sandwich
immunoassay. Both oxidized cotton and FFI systems can be used to develop new POC assays
quickly and economically. Future use of these POC systems could help expand the availability of
diagnostic testing to disadvantaged areas.
Gold-based drugs have been used and investigated as medications multiple times
throughout history to treat various diseases such as Rheumatoid arthritis, parasitic infections, and
cancer. In the last few decades, gold nanoparticles have been used as drug delivery agents and
catalysts for various reactions. Recently catalytic gold nanocrystals have been characterized for
their ability to treat neurodegenerative diseases. Although these results were promising, much is
still unknown about their mechanism of action. Section two of this thesis investigates potential
molecular pathways that gold nanocrystals could be affecting, specifically the IL-6/Jak/STAT3
inflammation pathway and the Nrf2 antioxidant pathway. The gold nanocrystals we tested did not
affect these pathways at physiologically obtainable concentrations. Additional work was done to
characterize protein interactome or protein corona of gold nanocrystals. Preliminary proteomic
characterization of this protein corona in fetal bovine serum (FBS) identified 118 potential
interactors and classified those based on function and structure. Future work will need to be done
to follow up on these identifications and to determine what mechanistic implications they may
have.
Keywords: POC diagnostics, oxidized cellulose, gold nanoparticles, protein corona
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SECTION 1: MODIFIED BIO-DIAGNOSTIC TESTS
BACKGROUND
Before a patient can receive treatment for a disease, they first have to know that they have
that disease. The process by which a patient discovers their ailment is known as diagnosis.
Diagnosis is a crucial though often overlooked area of medicine. Trained professionals can
diagnose patients based on descriptions of symptoms from the patient, but this means that the
disease has to have symptoms and that the patient has to communicate them effectively. Diseases
with few or ambiguous symptoms can be missed in this way. Another issue that arises from
diagnosis by symptoms is that one symptom can often be implicated in many conditions. An online
article about headaches by the Mayo Clinic details 52 possible causes of headaches ranging from
dehydration to cancer.1 Because of this complexity, it is essential to accurately measure specific
molecular disease biomarkers that can assist in diagnosis; this is accomplished using in-vitro
diagnostics or bio-diagnostics.
Bio-diagnostics are tests that look for specific molecular biomarkers to assist in the
diagnosis of disease and other conditions. Worldwide, there is a great need for in-vitro diagnostics,
especially in countries with low socioeconomic status. In 2018 the World Health
organization published the first essential list of bio-diagnostic tests naming 113 tests necessary to
advance universal health coverage, address health emergencies, and promote healthier
populations.2,3 This focus emphasizes that even if a country has access to great medicine, it will
not administer it effectively or efficiently if it cannot correctly diagnose disease in individuals
using bio-diagnostics.
Some commonly used bio-diagnostics techniques include qPCR and RT-PCR, enzymelinked immunosorbent assays (ELISA’s), western blotting, mass spectrometry, and

1

immunological-based assays. While many of these bio-diagnostics are very sensitive and accurate,
they can only be run in medical laboratories with expensive equipment and technically trained
personnel. Unfortunately, these laboratories are only accessible when infrastructure and funding
are sufficient, which often means that rural and low-income locations will lack access to such
facilities. Because of this disparity, there is a high demand for point-of-care (POC) diagnostics.
POC diagnostics are diagnostics that can be administered in any clinic or even at home
with a quick return of results. POC testing decreases the amount of time to diagnosis, reduces cost,
increases clinical efficiency, and increases patients' ability to participate in their treatment.4,5 POC
diagnostics need to provide quick and non-complicated results, making it essential that these tests
have a simple readout without needing advanced equipment to image the product. The World
Health Organization outlined an ideal standard for POC testing named the ASSURED criteria:
Affordable, Sensitive, Specific, User-friendly, Rapid and robust, Equipment-free, and Deliverable
to end-users.4 These criteria focus not only on accuracy and sensitivity but also on affordability
and ease of use. These criteria are especially important to allow distribution and use of tests in
countries that lack the infrastructure for more complicated diagnostics.
One of the essential parts of POC assays is obtaining a simple signal that can be read
immediately. One common technique is to use colorimetric assays, in which a color change or an
appearance of color corresponds to the diagnostic state being probed. Colorimetric tests can help
avoid the use of complicated imaging apparatuses and make the tests easier to administer. One
common way to add colorimetric character to a bio-diagnostic is by using nanoparticles. Due to
the plasmon resonance exhibited on the surface of nanoparticles, a solution of nanoparticles can
appear red, pink, green, blue, or another color depending on the nanoparticles' size and shape.6 The
most commonly used nanoparticles are gold nanoparticles because they are easy to synthesize, and
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antibodies can be easily conjugated to gold surfaces both passively and actively, giving a high
degree of flexibility in selecting analytes.7
One commonly used POC diagnostic technique that utilizes gold nanoparticles is the
Lateral Flow Immunoassay (LFI). LFI’s are a type of immunological sandwich assay that works
by capillary action and generally consists of four parts: a sample pad, a conjugate pad, a test strip,
and an absorbance pad (figure 1). A sample containing an analyte is added to the sample pad,
which wicks the sample up the strip. As the analyte passes through the conjugate pad, gold
nanoparticles conjugated to an antibody against the analyte bind to the analyte and are also wicked
up the strip. Capillary flow continues to carry the analyte-antibody-nanoparticle complex up the
test strip until they encounter another line of antibodies stuck to the strip specific to the analyte.
These antibodies catch the analyte and form a sandwich (antibody-analyte-antibody-gold
nanoparticle), which creates a visible line on the test strip due to the gold nanoparticles'
aggregation. Also usually included on the test strip is a control line with antibodies specific against

Figure 1: Lateral Flow Immunoassay Schematic. A: Sample containing analyte is added to the sample pad. B: Capillary action
wicks the sample up past the conjugate pad and binds to antibodies against that analyte conjugated to gold nanoparticles. C: The
sample continues to flow up the strip and past test antibodies against the analyte and control antibodies against the conjugate
antibodies. D: If the test is negative (contains no analyte) only the control line will appear, if the test is positive both the test and
control line will appear.

3

the antibodies conjugated to the gold nanoparticles. This line serves as a control to show that the
test has been appropriately run (antibody-antibody-gold nanoparticle). The absorbent pad at the
top of the LFI acts as a sponge, wicking up the sample and encourages capillary action.
Pregnancy tests are common LFI’s that detect the presence of human chorionic
gonadotropin (HCG), a protein upregulated during pregnancy, to provide evidence of a pregnancy.
Another well-known LFI is the COVID19 rapid antigen test. Both pregnancy and COVID19 LFI’s
have similar readouts: a single line indicates that the test has run correctly but that the result is
negative, two lines indicate a positive result, no lines or no control line means that the test has not
run correctly and needs to be redone.
Lateral flow immunoassays are extremely useful POC diagnostics that can be adapted to
test for almost any analyte as long as antibodies against the analyte exist. Even so, the design and
development process can make the production of new LFI’s time-intensive. Good antibody pairs
have to be found, conjugate pad composition has to be optimized, and specialized buffers for
analyte extraction may need to be tested. All of these factors can slow the rate at which a new LFI
is brought from the lab bench to the user’s hands which can be very detrimental to communities
when needed quickly. These limitations were evident during the beginning of the COVID19
pandemic. It took developers several months to develop the COVID19 Rapid antigen LFI tests,
allowing the disease to spread for those extra months.8 Quicker development of LFI’s could help
reduce future pandemics' effects.9
While LFI’s are simple to use, the complexities in development mentioned above make it
difficult for low-funded laboratories to make new LFI’s. While this may not be a problem in the
United States, developing countries should not have to wait for a benevolent 1st world nation to
meet their diagnostic needs. One goal of this research project is to develop methods to make new
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POC assays for measuring biomarkers quickly and easily with little equipment so developing
countries can meet their own bio-diagnostic needs.
In addition to the limitations mentioned above, LFI’s do not work with every type of
analyte. Analytes not in an aqueous solution have to be solubilized before an LFI can be used. If
an analyte is not soluble in an aqueous fluid, then complicated extraction/solubilization buffers
will be needed. Additionally, some biological vectors are challenging to use in LFI formats due to
their high viscosity, impeding capillary flow. Saliva is an example of a biological vector that is
difficult to use in an LFI, mainly because of its high mucus content.
These factors show that while LFI’s are fantastic point-of-care assays, they are not ideal in
every situation. New POC bio-diagnostics are needed to provide diagnosis in areas that LFI’s
cannot. The purpose of this section of my thesis is to outline potential materials and strategies that
can be used in future POC tests to accomplish this.
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CHAPTER 1: Oxidized Cellulose in Point of Care Diagnostics
Introduction
Traditionally, the test strip on the LFI strips is made out of nitrocellulose, which binds
strongly to proteins with hydrophobic and electrostatic interactions. While nitrocellulose works
well in LFI applications, it has several physical limitations, such as becoming brittle when dry,
moderate absorbency, and low flexibility. Additionally, if the purchase of nitrocellulose is not
financially feasible, the preparation of nitrocellulose in a low-income setting is dangerous because
concentrated nitric acid and sulfuric acid are required during the manufacturing process and
because nitrocellulose is highly flammable. The poor absorbency of nitrocellulose also slows
diagnostic runtime and necessitates the use of absorbent pads. These factors make nitrocellulose
challenging to use in some styles of bio-diagnostics. Because of these issues, we decided to explore
another protein-binding material that can easily be made in a lab with minimal resources as an
alternative to nitrocellulose: oxidized cellulose.
Cellulose is a polysaccharide made from β(1-4) linked D-glucose chains. When placed with
a potent oxidizing agent (such as potassium periodate), the glucose subunits open up between
carbon-2 and carbon-3, forming two aldehydes on either end (figure 2).10,11 Proteins can be added

Figure 2: Reaction of Cellulose with Potassium Periodate. KIO4 oxidizes carbons 2 and 3 of each glucose monomer, opening the
ring and forming two aldehyde groups. Antibodies or other polypeptides can then react with those aldehydes (via n-termini or
lysine groups) to form Schiff bases causing them to adhere firmly to the cellulose material.
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to the oxidized cellulose, and the aldehydes will form Schiff bases with amines (from lysine’s or
N-termini) from the protein. These strong bonds make oxidized cellulose an excellent platform for
protein immobilization in a host of potential applications.
Oxidized cellulose has been studied extensively for its physical, chemical, and biological
properties. Oxidized cellulose can effectively bind and immobilize trypsin12,13, catalase14,
hormones15, and antibodies16–18. Because of its ability to immobilize antibodies, oxidized cellulose
is a fantastic material to use in immuno-bio-diagnostics. Previous publications have used oxidized
cellulose to immobilize antibodies for various bio-diagnostics, including ELISA’s18, colorimetric
paper discs19, and even electrochemical immunosensors20. Another study used an oxidized
cellulose cotton swab to immobilize lactoferrin and then use those lactoferrin swabs to probe for
bacteria on surfaces in a colorimetric assay.21
We decided to explore the oxidation of easily accessible cellulose materials made from
cotton and other plant fibers and probe their ability to function in an immunological sandwich
assay. By characterizing easy-to-find materials found in almost every country on Earth, we hope
to provide more accessible methods and materials for anyone to develop their own POC assays.
Due to the ease of manufacturing and flexibility of use, we chose to characterize cotton balls,
printer paper, several different kinds of cotton fabrics, rayon fabric, and hemp string.

Experimental
Periodate Oxidation - General
1 liter of 0.03 M KIO4 was prepared on the day of use by adding 6.9 g KIO4 1 liter of
distilled/deionized water. This solution was loosely capped and mixed with a magnetic stir bar on
a hot plate at 90 °C until all KIO4 was utterly dissolved (about 45 minutes). Each cellulose material
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was submerged in KIO4 solution and incubated for 2 hours at 65 °C. Excess KIO4 was removed,
and the oxidized cellulose was washed three times with distilled water and left out to dry at room
temperature.
FTIR
Fourier Transform Infra-Red (FTIR) spectroscopy was performed on a Nicolet 6700 FTIR
spectrometer (Thermo Scientific) using a Small Orbit Diamond ATR apparatus (Thermo Fisher)
with an absorbance range between 30,000-200 cm-1. 50 scans measuring absorbance at a
resolution setting of 6 were performed for each cellulose material and its oxidized derivative.
OMNICTM (Thermo Fisher) IR analysis software was used to analyze and superimpose peaks. The
appearance of a peak at 1740-1720 cm-1 indicated the presence of aldehyde carbonyls and
suggested successful oxidation of cellulose to dialdehyde cellulose.
Immobilization of Antibodies
5 µL of goat anti-mouse antibodies (Invitrogen catalog#: 31160) were pipetted onto a small
piece of each oxidized material and nitrocellulose. These materials were dried entirely and then
the cotton substrate with any remaining activated aldehyde functional groups was inactivated by
blocking for 1 hour by shaking the cotton substrate in 5% powdered milk in distilled deionized
water. At the end of 1 hour, the milk was removed and the materials were rinsed three times in
distilled water. The cellulose material conjugated to antibodies was stored at 4 °C.
Dot Blot Sandwich Assay
To test for binding, anti-mouse immobilized materials were soaked in 5 mL of 10% v/v of
a gold nanoparticle solution conjugated to mouse anti-HCG antibodies (Fitzgerald catalog#: 62H25C) in TBS-T (Tris Buffered Saline-Tween-20) for 1 hour shaking. Gold-solution was removed,
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and materials were rinsed three times with distilled water. Materials were dried overnight at room
temperature. Gold staining was imaged on Canon CanoScan 8800F scanner at 1200 DPI, and
contrast was adjusted to give optimal intensity.
Cotton Swab Test
Cotton swabs were oxidized as described and treated with 3 µL of goat anti-mouse
antibodies near the shank and 3 µL of mouse anti-HCG antibodies (MyBioSource catalog#:
MBS832263) at the tip. Cotton swabs were blocked and dried as before. Cotton swabs were tested
in 1 mL of 10% v/v gold-mouse-anti-HCG in TBS-T with a tenfold serial dilution of HCG: 10,000
ng/mL, 1,000 ng/mL, 100 ng/mL, 10 ng/mL, 1 ng/ml, and compared to a control of 0 ng/mL. These
soaked for 3 hours and were then rinsed three times in distilled water. Pictures of cotton swabs
were taken using a phone camera

Hemp String Test
Hemp string was oxidized as before, treated with 5 µL of anti-mouse antibody and 5 µL of
anti-HCG antibody, and blocked as before. This exposed string was placed in 100 µL 10% v/v
gold-mouse-anti-HCG TBS-T with 10,000 ng/mL, 1,000 ng/mL, 100 ng/mL, 10 ng/mL, 1 ng/ml,
and a control of 0 ng/mL of HCG. These tests were allowed to sit for 10 minutes, wicking up the
test fluid. At the end of ten minutes, the tests were rinsed with distilled water three times. Gold
staining was imaged on the Canon CanoScan 8800F scanner at 1200 DPI, and contrast was
adjusted to give optimal intensity.
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Cotton Tube Test
Small pieces of cotton fabric were oxidized as described, treated with 5 µL of anti-mouse
antibody or 5 µL of anti-HCG antibody, and blocked as before. When dry, these cotton pieces were
bunched up and inserted into a clear plastic tube, and then held into place with smaller plastic
tubes. Each plastic tube made contained one anti-mouse piece of cotton and one anti-HCG piece
of cotton. These tests were run by pushing 1 mL of 10% v/v gold-mouse-anti-HCG in TBS-T
through the tube with 10,000 ng/mL, 1,000 ng/mL, 100 ng/mL, 10 ng/mL, 1 ng/ml, or a control
with 0 ng/mL HCG present. This 1 mL solution was pushed over the cotton 5 times with a syringe,
and then the test was rinsed with 15 mL of distilled water. Gold staining was imaged on the Canon
CanoScan 8800F scanner at 1200 DPI, and contrast was adjusted to give optimal intensity.

Results
Periodate Oxidation
Eleven different cellulose materials were oxidized using KIO4, a potent oxidizing agent.
These materials included cotton balls, printer paper, duck canvas, flannel, cheesecloth, sateen, bull
denim, twill, hemp string, and lyocell/rayon. FTIR was used to confirm that these materials were
successfully oxidized by monitoring for aldehyde groups' presence in the material (figure 3). The
appearance of a peak at 1740-1720 cm-1 indicated the presence of aldehyde carbonyls and
suggested successful oxidation of cellulose to dialdehyde cellulose. All materials showed the
presence of aldehyde groups to varying degrees when oxidized.
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Figure 3: FTIR of Oxidized Cellulose Materials. Each of the listed cellulose-based materials were oxidized and compared to unoxidized
material using FTIR. The appearance of aldehyde IR absorbance between 1710 and 1740 cm-1 indicated that the material had been
successfully oxidized when compared to the spectra from unoxidized cellulose.
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Sandwich Assay Characterization
We confirmed that each of the 11 oxidized materials can bind antibodies by immobilizing
anti-mouse antibodies to each material and incubating them with gold nanoparticles conjugated to
antibodies from mice (figure 4). We also included a nitrocellulose membrane in our trials as a
comparison. Every material stained pink where the antibodies had been added, indicating that the
antibodies had been successfully immobilized. The staining pattern for each had a different shape
and spread depending on the density of the material and the tightness of the weave.
We then chose a subset of these materials to create new tests in a sandwich assay format,
probing for HCG, the pregnancy hormone. We decided to probe for HCG because it is the focus
of pregnancy tests which makes it an extremely well-developed area of bio-diagnostics with

Figure 4: Test of Oxidized Cellulose Materials. The above oxidized cellulose materials dotted with anti-mouse antibodies
were treated with gold nanoparticles conjugated to mouse antibodies for one hour. This resulted in the colorimetric
readout seen above.

12

readily available supplies. This allowed us to easily compare the efficiency and efficacy of these
materials we tested to market available LFI’s. These tests are described in the following three
sections.
Cotton Swab Test
Using the materials we characterized above, we set out to make and characterize new POC
platforms utilizing immunological sandwich assays focusing on HCG as a model, but with the
hope that they could be applied to any analyte in the future. The first assay we created was the
cotton swab immunoassay (figure 5). Here we oxidized a cotton swab on a wooden shaft and
immobilized anti-mouse antibodies close to the shaft (as a positive control) and anti-HCG
antibodies at the tip. This assay was performed by placing the cotton swab in a solution containing

Figure 5: Cotton Swab Test. A: Schematic showing oxidized cotton swab immobilized with test antibodies against the
analyte of choice and control antibodies against the conjugate antibodies. When analyte and gold-nanoparticles
conjugated to an antibody against that analyte are incubated with the cotton swab test, two pink dots appear indicating
a positive test. If no analyte is present, only the control dot will appear indicating a negative test. B: Limit of Detection
of Cotton Swab Test For HCG. Oxidized cotton swabs dotted with anti-HCG antibodies and anti-mouse control
antibodies were placed in solutions containing varying amounts of HCG mixed with mouse-anti-HCG antibodies
conjugated to gold nanoparticles. The lowest signal obtained in these tests came from a 100 ng/mL HCG in solution.

13

HCG and gold nanoparticles for 2 hours. When removed and washed, the presence of two dots
meant the test was positive. The appearance of one dot meant the test was negative. We performed
a limit of detection assay on the cotton swab test and found that the cotton swabs could faintly
detect as low as 100 ng/mL of HCG (figure 5B).
String Test
The second assay we created was based on hemp string. We immobilized anti-mouse and
anti-HCG antibodies on an oxidized hemp string (figure 6). This test was placed with the end of

Figure 6: Hemp String Test. A: Schematic showing oxidized hemp string immobilized with test antibodies against
the analyte of choice and control antibodies against the conjugate antibodies. When analyte and gold-nanoparticles
conjugated to an antibody against that analyte are incubated with the hemp string, two pink lines appear indicating
a positive test. If no analyte is present, only the control dot will appear indicating a negative test. B: String Test
Limit of Detection with HCG. Oxidized hemp string tests dotted with anti-HCG antibodies and anti-mouse control
antibodies were placed in solutions containing varying amounts of HCG mixed with mouse-anti-HCG antibodies
conjugated to gold nanoparticles. The lowest signal obtained in these tests came from a 100 ng/mL HCG in solution.
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the string hanging in 100 µL solution of HCG and gold nanoparticles. The solution was then
allowed to wick up the hemp string for 10 minutes until all liquid was gone. The string was then
rinsed with water to reveal the gold stains. Two stains indicated a positive test, while one stain
indicated a negative test. We also performed a limit of detection assay on the hemp string test and
found that it could detect as low as 100 ng/mL of HCG (figure 6B).
Cotton Tube Test
The third assay we created used small pieces of cotton fabric immobilized with either antimouse or anti-HCG antibodies. For each test, one anti-mouse, one anti-HCG, and one blank piece
of cotton were bunched up and inserted into a clear plastic tube and held into place with clear
plastic inserts (figure 7). This test was run by pushing 1 mL of a solution of HCG and gold
nanoparticles conjugated to anti-HCG antibodies through the tube five times with a syringe and

Figure 7: Cotton Tube Test. A: Schematic of showing oxidized pieces of cotton immobilized with test antibodies against the analyte
of choice and control antibodies against the conjugate antibodies and control antibodies packed into a clear plastic tube and held in
place by plastic spacers. When analyte and gold-nanoparticles conjugated to an antibody against that analyte are pushed through
the test with a syringe, two pieces of cotton will turn pink indicating a positive test. If no analyte is present, only the control piece of
cotton will turn pink indicating a negative test. B: Limit of Detection of Cotton Tube Test for HCG. Cotton tube tests containing
cotton dotted with anti-HCG antibodies and anti-mouse control antibodies were run through solutions containing varying amounts
of HCG mixed with mouse-anti-HCG antibodies conjugated to gold nanoparticles. The lowest signal obtained in these tests came
from a 1,000 ng/mL HCG in solution.
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then rinsing it with water until the blank negative control was white again. The test was positive if
the top two cotton pieces remained stained and negative if only one piece of cotton remained
stained. We also performed a limit of detection assay on this cotton-in-a-tube test and found that
it could detect as low as 1000 ng/mL of HCG (figure 7B).

Discussion
In this chapter, we established that many different kinds of cellulose-based materials could
easily be oxidized and used as a platform for antibody immobilization in immunological sandwich
assays. We also provided three examples of possible POC assays that can be made with these
materials and demonstrated their potential effectiveness by providing their limit of detections for
HCG. The threshold of HCG present in a sample for a woman to be considered pregnant is 24
mIU or approximately 2,400 ng/mL. All of our oxidized cellulose assays detected well below this
mark, showing that these tests could be viable in a real-world setting. We only tried one antibody
pair that was known to work well for HCG in these experiments. The detection limits for diseaserelevant biomarkers with different antibody pairs could obtain an even lower limit of detection.
We developed these three tests in the course of 6 months with only the cellulose materials,
potassium periodate, antibodies, and gold nanoparticles. I believe that these and other tests could
easily be developed by low-income laboratories because no specialized equipment was required
for the development. The main hurdle in resource-poor areas would be obtaining antibodies for the
antigen of choice. Still, with ever-expanding antibody industries, I hope that antibodies will
continue to lower in cost and become more available to low-income areas. It is also possible that
the World Health Organization or humanitarian agencies could aid these countries to purchase
antibodies to make POC tests.
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The cost of materials for the cotton swab test, hemp string test, and cotton tube test were
all very low, with most of the cost coming from the antibodies and pre-conjugated gold
nanoparticles in each case. Admittedly, antibodies make up the bulk cost of most immunediagnostics. Mass production of these tests could help bring down these antibody costs.
Further exciting possibilities exist for the POC assays we have presented here. The cotton
swab test could potentially be used as both a means to collect a sample from a surface (a tabletop,
toilet seat, oral cheek swab, or nasopharyngeal swab) and to act as the actual test itself. This would
decrease complexity and increase user ease-of-use. With its increased absorbency, the hemp string
test could be used in situations where LFI’s cannot wick analyte quickly, such as saliva or other
complex vectors. Additionally, one could imagine an LFI made of one of these oxidized cellulose
materials, eliminating the need for sample or absorbance pads due to these cellulosic materials'
natural absorbency. Of course, further testing will need to be done to ensure that each of these
possibilities would work in user-friendly ways.
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CHAPTER 2: Fast Flow Immunoassays (FFI’s)
Introduction
One of the significant limitations that frequently comes up during LFI development is that
of sensitivity. The most significant factor determining how sensitive an LFI or other sandwich
assay will be is how sensitive the antibodies are. The process of choosing suitable antibodies needs
to be well thought out and carefully tested. There are, however, other ways to increase sensitivity
if the sensitivity of a given pair of antibodies is lacking. One issue that LFI’s have is that there is
only one relatively short chance for the analyte to bind to the test strip. Analyte gets one chance,
and if the flow is too fast or the binding too weak, the signal will also be weak. One way to increase
signal would be to allow the analyte multiple opportunities to bind to the immobilized antibodies
on the test strip. This chapter describes our attempts to create a more sensitive test that bypasses
the need for a one-pass capture by capillary action. This was done by passing the sample over the
capture antibodies multiple times.
We designed a test platform that would be able to meet the needs described above. It
consists of a syringe filter adaptor encasing a nitrocellulose filter immobilized with antibodies. In
this test, a sample is forced through the disk using a syringe, making the test rely on hand power
rather than capillary action. After being pushed through once, a sample can be run through the test
additional times with minimal effort to increase the opportunities that the analyte has to bind with
the capture antibodies. We named this POC assay that we created the Fast Flow Immunoassay
(FFI) (figure 8).
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The FFI syringe filter head consists of two adaptors that can be threaded together. The top
piece has a Luer-lock adaptor for attachment to a plastic syringe. The bottom piece has a skinny
dispenser from which sample is expelled. A sieve supports a nitrocellulose filter containing
immobilized antibodies in the middle where the two pieces thread together. The metal sieve and
the nitrocellulose filter are locked in place with O-rings when the two parts are threaded together.
This test is run by taking up the analyte mixed with gold nanoparticles conjugated to antibodies
specific to that analyte in a syringe. This mixture is then pushed through the metal syringe filter.
The eluted liquid is collected in a tube on the other end and can be passed through the filter multiple
times to increase the signal. This test's signal will appear as a pink dot on the nitrocellulose due to
the aggregation of gold nanoparticles forming an immunological sandwich between the
nitrocellulose, capture antibody, analyte, conjugate antibody, and gold nanoparticle.

Figure 8: Fast Flow Immunoassay Schematic. The FFI filter head from top to bottom consists of a metal
casing with a luer lock adaptor, an O-ring, a nitrocellulose filter dotted with antibodies against an
analyte, a metal filter, another O-ring, and the rest of the metal casing with a dispensing end. These are
assembled by threading the two ends together. The test is run by pushing analyte and gold nanoparticles
conjugated to antibodies against that analyte through the filter head with a syringe. This can be repeated
multiple times to increase signal. When complete the nitrocellulose filter is removed, if a pink dot has
formed, it is a positive test; if not it is a negative test.
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We tested the FFI in its ability to increase signal and sensitivity in a given test. We also
compared the sensitivity of FFI’s to a dot blot sandwich assay on nitrocellulose using the same
antibodies and gold nanoparticles in both tests. Finally, we found the limit of detection of our FFI
when using antibodies to detect HCG, the pregnancy hormone.
Experimental
Immobilization of Antibodies on Nitrocellulose Discs
5 µL of goat anti-mouse (Invitrogen catalog#: 31160) or mouse anti-HCG (MyBioSource
catalog#: MBS832263) antibodies were added to a small circular disc of nitrocellulose 11 mm in
diameter. These discs were dried entirely and then blocked for 1 hour, shaking in 5% Milk. At the
end of 1 hour, the milk was removed and the discs were rinsed three times in distilled water. These
were then placed at 4 °C overnight to dry.
FFI Multipass Test
A nitrocellulose disc was placed in the syringe adaptor on top of the metal sieve and locked
into place on either end with O-rings as the adaptor is threaded together. 1 mL of 10% v/v goldnanoparticle-mouse-anti-HCG (Fitzgerald catalog#: 62-H25C) in TBS-T was taken up in a 15 mL
plastic syringe. This solution was pushed through a syringe filter at a slow constant rate and
collected in a tube. These steps were repeated with the original solution multiple times to determine
if multiple passes of a sample over the filter increased the intensity. When complete, 10 mL of
distilled water was run through the syringe filter to remove excess gold, and the nitrocellulose
filter was removed.
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Dot Blots
Dot blots for comparison were completed by incubating nitrocellulose discs immobilized
with anti-mouse antibodies with 10% v/v gold-nanoparticle-mouse-anti-HCG in TBS-T. These
were incubated for 1, 3, 10, 20, 30, or 60 minutes. Each disc was washed three times in distilled
water and dried completely.

Limit of Detection
The limit of detection of anti-HCG FFI’s was tested by running those FFI’s as described
above with three passes each. These tests were run on serial dilutions of HCG: 10,000 ng/mL,
1,000 ng/mL, 100 ng/mL, 10 ng/mL, 1 ng/ml, and a control of 0 ng/mL. These tests were washed
three times in distilled water and dried completely. A pink dot indicated a positive test.

Scanning Tests
Gold staining was imaged on the Canon CanoScan 8800F scanner at 1200 DPI, and contrast
was adjusted to give optimal intensity. Scans were quantified using ImageJ software, measuring
each dot's average intensity, and normalizing that intensity to the average intensity of a blank
nitrocellulose filter. The resulting graphs show how many times more intense each test is than a
blank white nitrocellulose disc.
Results
Multipass Test vs Dot Blot
We tested how FFI’s could increase a test's signal by passing a sample through the filter
multiple times. We used nitrocellulose immobilized with anti-mouse antibodies and ran a solution
of gold nanoparticles conjugated to mouse-antibodies through it 1-10 times (figure 9). It took about
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one minute to pass the sample through the FFI filter one time. We observed a linear increase in
signal intensity for each additional pass, showing the ability FFI systems have to easily increase
signal intensity. We compared these samples to the sample nitrocellulose filters run on a dot blot
time course for up to an hour and found that the signal from the FFI system with only one pass

Figure 9: Increasing FFI Signal with Multiple Passes. A: The ability of the FFI system to increase signal by
passing sample over a nitrocellulose filter fixed with antibodies was tested with anti-mouse antibodies, and
gold nanoparticles conjugated to mouse antibodies. All filters shown are separate filters with the indicated
number of passes. A dot blot with the same filters and antibodies was done for 1 hour for comparison. B:
The quantification of the dot blots and multi-pass test. C: Multi-pass test up to 10 passes of the sample
through the filter. 10 passes resulted in ≈80x greater signal than a blank filter. D: Quantification of those
10 passes.
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was more than four times greater than the dot blot signal at 1 hour and that an FFI with five passes
had almost 12 times greater intensity, all while taking five minutes or less. These experiments
show that our fast flow system is both rapid and sensitive.
Limit of Detection of HCG FFI
We tested the limit of detection of the FFI system using a set of antibodies known to work
well to detect HCG in a sandwich assay. We found that the FFI with three passes could detect as
little as 100 ng/mL of HCG (figure 10). It took on average 3 minutes to obtain results for these
tests. As a comparison, we tested a commercially available LFI for HCG produced by Clinical
Guard in the same conditions. These HCG LFI’s and our FFI’s are not directly comparable because
they use different antibodies and gold nanoparticles. Even so, it was still usefully to compare the
FFI test against a market-ready test for HCG. The HCG LFI test took about the same amount of

Figure 10: FFI Limit of Detection for HCG. Nitrocellulose filters immobilized with anti-HCG antibodies were
tested against various concentrations of HCG mixed with gold nanoparticles conjugated to additional antiHCG antibodies. This solution was passed through the filter 3 times. These tests were run in triplicate The
lowest signal obtained in these FFI’s was 100 ng/mL HCG. Clinical Guard HCG LFI tests available on the
market were run under the same conditions for comparison. These were able to detect as low as 10 ng/mL but
did not use the same antibodies as the FFI.
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time to run as the FFI and had a lower limit of detection at 10 ng/mL. We suspect that these
differences are mainly due to differing antibody affinity, but this fact will need to be tested.
Discussion
We found the fast flow immunoassay system described here to be a rapid and sensitive
assay. The FFI was more sensitive to HCG than the dot-blot sandwich assay because it forced the
analyte through a small area, making it come in close contact with the capture antibodies (similar
to how LFI’s focus analyte through a small area via capillary action). The FFI also proved to be
more sensitive because the analyte could be passed through the filter multiple times, increasing
the signal with each pass.
In the experiments detailed above, we modeled the FFI in an ideal buffer situation. It would
be interesting to compare the functionality of an LFI and an FFI with the same antibody pairs in
different biological buffers (i.e. saliva, urine, serum). Testing other buffers would allow us to see
if the FFI would outperform the LFI in buffers that have traditionally been difficult to use in
capillary flow-based tests. Similarly, testing actual biological samples using the same two tests
will allow us to determine if there is a limit of detection benefit for patients. Even if the limit of
detection is identical, the faster results will allow the FFI to become an important method to use.
Combining ideas from chapter one and this chapter, it would be possible to make an FFI
system that utilizes an oxidized cellulose filter instead of nitrocellulose. We briefly tested this
possibility (data not shown) and found that oxidized cotton works just as quickly in an FFI system
as nitrocellulose. The use of oxidized cellulose in FFI’s is another avenue that can be explored in
the future to reduce the cost of this test and perhaps increase the ease-of-use by using materials
that samples can flow through easily.

24

One great benefit that FFI systems could have is facilitating quicker development of POC
bio-diagnostics in times of need. When a new biomarker for a disease is discovered (like the spike
protein of SARS-CoV-2), antibodies must first be raised against that bio-marker before
immunological-based assays can be developed. These antibodies are made by injecting the new
bio-marker into animals and waiting for the animal to develop them. The first antibodies produced
from this process are usually weak with low binding affinities. Over time antibodies with higher
binding affinities can be produced, but this takes time, and making more robust antibodies is not
always possible. The FFI could help these weaker antibodies function in POC assays because of
its ability to improve a test's sensitivity by running the sample multiple times. Helping weaker
antibodies perform in POC assays would facilitate quicker development of important tests by
assisting early iterations of ineffective antibodies to be sensitive enough.
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SECTION 2: GOLD NANOPARTICLES AS A MEDICINE
BACKGROUND
The concept of gold as a medicine is not a new one. Though traditionally valued for its
inert and non-reactive character, gold can be a very effective catalyst at the nano and molecular
level, as in the case of nanoporous gold.22 Early unsuccessful applications of gold in medicine
attempted to treat tuberculosis with gold.23 Later on, it was found that gold as a part of an organic
molecular platform could successfully treat autoimmune and inflammatory diseases such as
rheumatoid arthritis.24
In the last decade, gold nanoparticles have been used as a platform to carry treatments to
treat a variety of diseases. Gold nanoparticles have been used as non-toxic carriers of drugs and
nucleic acids to tumor sites for various kinds of cancer.25–28 They have also been used in
photothermal therapy, in which a tumor treated with gold nanoparticles is irradiated with laser
light exciting the gold nanoparticles, causing an increase in temperature and killing the cancer cells
as a result.28 It has also been hypothesized that gold nanoparticles themselves could inhibit
angiogenesis, staving off tumors' growth.28
Gold nanocrystals are a special category of gold nanoparticles in which particles are formed
by the nanocrystalline assembly of gold. Gold nanocrystals appear to have more catalytic abilities
than normal spherical nanoparticles due to their edges and corners.29,30 Recently a uncapped
catalytic gold nanocrystal was reported by Robinson et al. to be able to treat Multiple Sclerosis, a
neurodegenerative disease caused by the demyelination of neuronal axons .31 This gold nanocrystal
was shown to catalyze the oxidation of NADH to NAD+. Its ability to catalyze this reaction was
implicated in its ability to facilitate remyelination in models of multiple sclerosis.31 Because of
those encouraging results, gold nanocrystals are currently undergoing phase II clinical trials other
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neurodegenerative diseases including multiple sclerosis32, Parkinson’s disease33, and Amyotrophic
Lateral Sclerosis (ALS).34
While the above results are encouraging, they were pursued only in oligodendrocytes and
in no other cell type. Additionally, little is known about molecular pathways that gold nanocrystals
could be affecting directly or indirectly. We decided to investigate potential molecular pathways
that gold nanocrystals could be affecting in liver tissue-cell culture to find new potential
therapeutic effects or possible off-target effects. We chose to explore these interactions in liver
cell culture because the liver is the center of metabolic activity in the body and essential in
understanding drug-body interactions. The two molecular pathways we chose to explore based off
of the literature were the IL-6/Jak/STAT3 inflammatory pathway, and the Nrf2 antioxidant defense
pathway.
In addition to investigating molecular pathways that gold nanocrystals could be affecting,
I decided to explore their direct protein interactors, the protein corona, in a proteomic style
experiment. By ascertaining the composition of gold nanocrystals protein corona, I hoped to better
understand their interactors and disposition. I decided to characterize this protein corona in fetal
bovine serum (FBS) because FBS is an easily attainable model of human serum, and serum
interaction can greatly determine the disposition and activity of a nanoparticle.35
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CHAPTER 3: Effects of Gold Nanocrystals on pSTAT3 Inhibition
Introduction
Auranofin is a gold drug used to treat rheumatoid arthritis, a debilitating autoimmune
disease in which the immune system attacks tissue surrounding the joints causing chronic
inflammations and pain in individuals affected with the disease.36 Auranofin is an S-glycosyl
compound consisting of 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranose with the sulfur atom
coordinated to triethyl-phosphine gold (figure 11B). Studies have also shown that Auranofin may
have some ability to treat HIV37, Tuberculosis38, Amebiasis39, Ovarian cancer40, and possibly
COVID-19.41
In a 2007 paper, Kim et al. were able to show that Auranofin effectively inhibits the
phosphorylation of STAT3 by JAK1 in liver tissue culture.42 The Jak/Stat pathway is activated by
Interleukin-6 (IL-6) which regulates inflammation, proliferation, and differentiation of many
different types of cells.43 This pathway plays a key role in causing chronic inflammatory pain in
rheumatoid arthritis and other chronic inflammatory diseases.44 The pathway is triggered when IL6 cytokine binds to the membrane receptor GP-130 causing dimerization and autophosphorylation
of the associated JAK kinase. The JAK kinase then phosphorylates STAT3 at Tyr705 and Ser727,
causing dimerization and translocation to the nucleus. In the nucleus, the STAT3 dimer acts as a
transcription factor upregulating genes involved in inflammatory and other pathways. This
pathway scheme is shown here in figure 11a. Kim et al. were able to show that Auranofin inhibited
the phosphorylation of STAT3 by JAK1 in a dose-dependent manner in cell culture that was treated
with IL-6 (figure 11b). They found that these effects were negated when cells were co-incubated
with thiolated small molecules, which would bind to the gold in theory. These results suggest that
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Auranofin inhibits STAT3 phosphorylation by binding to some thiolated intermediate in that
pathway.42
We hypothesized that other gold compounds could have a similar effect on liver tissue
culture cells. Specifically, we thought that gold nanocrystals (with a diameter of 15 nm) might also
be able to inhibit the phosphorylation of STAT3, especially because it would have a larger gold
surface area with which thiolated intermediates could interact.

Figure 11: IL-6/Jak/STAT3 Inflammation Pathway. A: IL-6 binds to cellular GP-130 transmembrane receptor inducing
conformational changing activating and phosphorylating Jak Kinase. Jak kinase phosphorylates STAT3 causing it to dimerize and
translocate to the nucleus. Once in the nucleus, the pSTAT3 dimer acts as a transcription factor activating genes that related to
the inflammatory response. B: Auranofin, a gold-based drug is known to inhibit this pathway by preventing the phosphorylation
of STAT3 to pSTAT3.

Experimental
HepG2 Cell Culture and Treatment
HepG2 liver epithelial cells were cultured at 37 °C with Eagles Minimum Essential
Medium (EMEM) supplemented with 10% FBS and 100 units/mL penicillin.

Cells were

maintained between 50% - 80% confluent and split at a 1:5 ratio when 80% - 90% confluent at
low passage number (<20 passages). Cells were treated with 0.05% trypsin until adherence was
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lost. The cellular solution was centrifugated at 1000 RPM for 4 minutes. The supernatant was
discarded, and cells were resuspended in supplemented EMEM media. Resuspended cells were
plated at 1/5 of their original concentration.
For treatment, cells were split and plated at a density of 5x106 cells/mL and grown
overnight. The following day cells were induced with 20 ng/mL IL-6 to induce the IL-6/Jak/STAT
pathway and then treated with different concentrations of gold nanocrystals either concurrently or
preemptively. Induced and treated cells were incubated at 37 °C for 24 hours unless otherwise
noted.

Lysis
After treatment, media was removed, and cells were washed three times in sterile PBS
buffer while on ice. Cells were isolated by centrifugation at 1000 rpm at 4 °C for 4 minutes,
followed by removing the PBS supernatant. Cells were lysed by adding 200 µL RIPA buffer (150
mM NaCl, 50 mM Tris-Base, 0.5% Sodium Deoxycholate, 0.1% SDS, 1% Triton-X, one aliquot
of HALT (Thermo Fisher catalog#78430) protease inhibitor cocktail/10 mL RIPA) and then flashfrozen in liquid nitrogen followed by immediate thawing in a 37 °C water bath. After thawing, the
lysate was pipetted up and down 10x in a 22-gauge needle to shear the DNA. Samples were then
centrifugated at 14,000 RCF for 30 minutes at 4 °C to pellet out the DNA.

Western Blotting
The amount of protein in each cell lysate was quantified using the protocol developed by
Lowry et al.45 Twelve bovine serum albumin (BSA) standards between 0 and 55 µg/mL were run
in duplicate and used to quantify each sample that was run in triplicate. 25 µg of each sample was
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combined with 5 µL of 5X loading dye (250 mM Tris-HCl pH 6.8, 10% SDS, 30% glycerol, 5%
β-Mercaptoethanol, 0.02% Bromophenol Blue) and heated at 95 °C for 5 minutes. Samples were
then centrifugated briefly and then added with a protein MW standard ladder (GoldBio #P007500) to separate lanes in a 1.5 cm 5% acrylamide stacking gel on top of a 12% acrylamide TrisSDS separating gel submerged in SDS-PAGE running buffer (25 mM Tris-Base pH 7.6, 200 mM
Glycine, 1% SDS). Loaded gels were run at 150 V for 60 minutes or until dye had reached the end
of the gel.
When SDS-PAGE gels had finished running, the gel was removed, rinsed with distilled
water, and placed on a nitrocellulose membrane, and sandwiched between two pieces of filter
paper and two sponges in a western blot cassette submerged in chilled transfer buffer (25 mM TrisBase pH 7.6, 200 mM Glycine, 20% methanol). The western blot cassette was placed in a transfer
tank filled with transfer buffer and chilled with ice. The protein was transferred from the gel to the
nitrocellulose membrane at 0.25 Amps (constant current) for 90 minutes.
When the transfer was complete, membranes were removed, rinsed with TBS buffer (10
mM Tris-Base pH 7.6, 150 mM NaCl), and then dried for 15 minutes. Once dried, the membranes
were rehydrated with distilled water and blocked in 5 mL of blocking buffer (10 mM Tris-Base
pH 7.6, 150 mM NaCl, 5% powdered milk, 0.1% tween-20) shaking for 1 hour. At the end of 1
hour, 2.5 µL of anti-phospho-Stat3 (Cell Signaling Rabbit mAB #9145) and 5 µL of anti-β-actin
(Cell Signaling Mouse mAB #3700) were added to the blocking solution and incubated at 4 °C
shaking overnight. The next day the antibody solution was removed, and the blot was washed 3x
for five minutes with TBS-T (10 mM Tris-Base pH 7.6, 150 mM NaCl, 0.1% tween-20). After
washes, 5 mL of blocking buffer with 1 µL of anti-rabbit (Licor Donkey #926-32213 800 nm
fluorescence) and 1 µL of anti-mouse (Licor Donkey #926-68072 680 nm fluorescence) secondary
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antibodies conjugated to fluorescent probes was added to the blots to incubate for 1 hour. At the
end of one hour, antibodies were removed, and the blots were rinsed three times with TBS buffer.

Western Blot Data Analysis
Blots were imaged on the LI-COR Odyssey® CLx scanner scanning for fluorescence at
680 nm and 800 nm. Images were processed and quantified using ImageStudio™ Lite software.
Pixel intensity was calculated for bands of interest. Two pSTAT3 bands at 79 and 86 kDa were
quantified in each lane on the 800 nm channel, and a single β-actin band at 42 kDa was quantified
in each lane on the 680 nm channel. To normalize samples, the pSTAT3 intensity was divided by
the β-actin intensity for every lane. For replicates across gels, each normalized intensity was
divided by the normalized intensity of the IL-6 positive control. Averages and standard deviations
were calculated for each sample across replicates. One-tailed heteroscedastic T-tests were
calculated against the IL-6 positive control sample. P-values less than 0.05 were considered
significant.

Results
Effect of Gold Nanocrystals on STAT3 Phosphorylation
To determine if gold nanocrystals can block the phosphorylation of STAT3 in a manner
similar to Auranofin, we replicated the study by Kim et al. by inducing the HepG2 liver epithelial
cells grown in tissue culture with IL-6 to turn on the JAK/STAT pathway. Cells were concurrently
treated with varying concentrations of gold nanocrystals and then analyzed for pSTAT3 levels
using western blotting. Figure 12A showed no reaction of pSTAT3 to the gold nanocrystals in the
presence of IL-6 (250 ppm) when smaller doses of the nanocrystals ranging from 0.01 to 2 ppm
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were used even as we confirmed that Auranofin effectively inhibits STAT3 phosphorylation.
Figure 12B told a similar story with gold nanocrystal concentrations between 15 and 75 ppm. It
wasn’t until concentrations were increased to 250 ppm in figure 12C that a significant reduction
in the levels of pSTAT3 was observed, suggesting that high concentrations of gold nanocrystals
could inhibit the phosphorylation of STAT3. To confirm that lower concentrations did not affect
pSTAT3, we performed a time course pre-incubating 1 ppm of the gold nanocrystals with HepG2
cells before the addition of IL-6. These results are shown in figure 12D and yielded no significant
reduction in pSTAT3 levels.

Figure 12: Inhibition of STAT3 to pSTAT3 with Gold Nanocrystals. IL-6 was using to induce inflammation and the phosphorylation
of STAT3 in HepG2 Cells while being treated with varying concentrations of gold nanocrystals. A-D show western blots and
quantifications. Blue graphs indicate only one replicate was used, orange indicates two replicates were used, and yellow indicates
three replicates were used. * p-value <0.05, ** p-value <0.01 A:Low gold nanocrystals concentration 0.01 -2 ppm. B: Midrange
gold nanocrystals concentration 15-75 ppm. C: High gold nanocrystals concentration 100-250 ppm. D: Preincubation time course
of HepG2 cells with gold nanocrystals before addition of IL-6 1 hour to 8 hours.
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Discussion
The gold nanocrystals were able to significantly inhibit the phosphorylation of STAT3 at
high concentrations of 250 ppm. Unfortunately, in data shared with us by the creators of the gold
nanocrystals we were using, the maximum physiological level of nanocrystals obtained in mice
was 1 ppm. Because of this data, we concluded that physiologically obtainable levels of the gold
nanocrystals would not serve as an effective inhibitor of Jak/Stat3 inflammation in the model of
liver inflammation tested here.
We included an Auranofin control in figure 12A showing that Auranofin effectively
inhibits the phosphorylation of STAT3 at small concentrations. It appears that the small organic
nature of Auranofin, as well as its gold composition, is necessary for it to be therapeutically active.
The gold nanocrystals we used are composed of approximately 68,000 gold atoms31 with a
molecular weight of 13,394 kDa, while Auranofin only has one gold atom with an organic scaffold
as a molecular weight of 0.679 kDa. This larger difference in size could explain the different
abilities of these gold nanocrystals and Auranofin to inhibit STAT3 phosphorylation.
While the gold nanocrystal’s size seems to set it apart from small gold medications, it
would still be interesting to probe other inflammation-related pathways that gold drugs have
targeted. Aurothiomalate is another gold-based drug used to treat Rheumatoid arthritis by
increasing MAPK phosphatase 1 expression.46 Future work could investigate the effects that gold
nanocrystals have on this MAPK phosphatase or other inflammatory pathways affected by other
gold-based medications. It is interesting to note that the gold nanocrystals, Auranofin, and
Aurothiomalate exhibit their therapeutic activity in autoimmune diseases (multiple sclerosis and
Rheumatoid arthritis). Perhaps there is still a yet undiscovered link between gold treatments and
autoimmune diseases.
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CHAPTER 4: Effects of Gold Nanocrystals on Nrf2 Activation
Introduction
To continue probing the biological effects of gold nanocrystals, we turned to a biological
pathway known to be affected by small gold nanoparticles: the Nrf2 pathway. Nuclear factor
erythroid 2-related factor 2 (Nrf2) is the master regulator of the antioxidant response elements.47
In a typical oxidative environment, Kelch-like-EH-associated protein 1 (KEAP1) induces the
ubiquitylation and degradation of Nrf2 via the proteasome in the cytoplasm before it can reach the
nucleus. When oxidative stress becomes high, an intracellular disulfide bridge is formed in KEAP1, causing a ‘kink’ to form in the protein preventing it from bonding with Nrf2.48,49 Nrf2 is then
free to travel to the nucleus and act as a transcription factor upregulating proteins like Heme
Oxygenase-1 (HO-1),49,50 NAD(P)H quinone oxidoreductase 1 (Nqo1),51 Sulfiredoxin 1,52
glutathione S-transferase,53 UDP-glucuronosyltransferase,54 and other proteins involved in
protecting against oxidative stress (Figure 13).
Nrf2 activation helps fight against harmful oxidative agents and is mainly cited for its
potential role in cancer protection as well as improve conditions for other diseases.55,56 That being
said, there is some controversy in the field that Nrf2 may not be beneficial in every circumstance.
Nrf2 has been implicated in the pathology of some cancers, in which its activation helps cancer
cells survive and proliferate.57 It appears that Nrf2 may be helpful or deleterious depending on the
case, but that for most healthy individuals Nrf2 activation appears to be a beneficial thing.58
Because of this fact, many papers have published potential activators of Nrf2 that could be
beneficial health supplements.59–63
In a 2015 paper, Lai et al. found that uncapped, spherical, gold nanoparticles 3-5 nm in
diameter were capable of inducing the expression of HO-1, a target of Nrf2.64 They discovered
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that this effect could only be disrupted by the presence of thiolated small molecules known to bind
to gold surfaces. In this study, they also found the gold nanoparticles did not produce reactive
oxygen species or induce ER stress. This led the authors to believe that these gold nanoparticles
did not have a toxic oxidative effect on tissue culture cells but could have a beneficial effect by
activating antioxidant response genes.64 Additionally, Auranofin the gold drug is a known activator
of Nrf2.65
Because other gold nanoparticles and gold medications have been associated with Nrf2
activation, we hypothesized that gold nanocrystals would also be a good activator of Nrf2 because
of its known ability to oxidize NADH to NAD+. We hypothesized that gold nanocrystals would be
able to oxidize KEAP1, thereby activating Nrf2. To test this, we treated HepG2 liver cell tissue
culture with varying concentrations of gold nanocrystal and then monitored the cell lysates for

Figure 13: Nrf2 Antioxidant Defense Pathway: A: Under normal conditions, Keap1 ubiquitinylates Nrf2 causing it to be degraded
by the proteosome. B: When an oxidative inducer such as small gold nanoparticles are added to a cell, Keap1 is inhibited and Nrf2
translocates to the nucleus. Once in the nucleus Nrf2 acts as a transcription factor and upregulates beneficial antioxidant gene
expression.

increases in HO-1, a protein product upregulated by Nrf2 activation.
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Experimental
HepG2 Cell Culture and Treatment
HepG2 liver epithelial cells were cultured at 37 °C with Eagles Minimum Essential
Medium (EMEM) supplemented with 10% FBS and 100 units/mL penicillin.

Cells were

maintained between 50% - 80% confluent and split at a 1:5 ratio when 80% - 90% confluent at
low passage number (<20 passages). Cells were split with 0.05% trypsin until adherence was lost,
and cells were isolated by centrifugation at 1000 RPM for 4 minutes. The supernatant was
discarded, and cells were resuspended in supplemented EMEM media. Resuspended cells were
plated at 1/5 of their original concentration.
For treatment, cells were split and plated at a density of 5x106 cells/mL and grown
overnight. The following day cells were induced with differing concentrations of gold nanocrystal
or one of three positive controls known to activate the Nrf2 pathway: 10 µm 2-Trifluoromethyl2'-methoxychalcone (Cayman Chemical #11881), 20 µm 3H-1,2-Dithiole-3-thione (Abcam
#AB141925), and 10 µm Sulforaphane (Sigma Aldrich #S4441). Treated cells were incubated at
37 °C for 6 or 12 hours, as noted.

Lysis
After treatment, media was removed, and cells were washed three times in sterile PBS
buffer while on ice. Cells were isolated by centrifugation at 1000 rpm at 4 °C for 4 minutes,
followed by the removal of PBS supernatant. Cells were lysed by adding 200 µL RIPA buffer (150
mM NaCl, 50 mM Tris-Base, 0.5% Sodium Deoxycholate, 0.1% SDS, 1% Triton-X, 1 aliquot of
HALT (Thermo Fisher catalog#78430) protease inhibitor cocktail/10 mL RIPA) and then flashfrozen in liquid nitrogen followed by immediate thawing in a 37 °C water bath. After thawing, the
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lysate was pipetted up and down 10x in a 22-gauge needle to shear the DNA. Samples were then
centrifugated at 14,000 RCF for 30 minutes at 4 °C to pellet out the DNA.

Western Blotting
The amount of protein in each cell lysate was quantified using the protocol developed by
Lowry et al.45 Twelve bovine serum albumin (BSA) standards between 0 and 55 µg/mL were run
in duplicate and used to quantify each sample that was run in triplicate. 25 µg of each sample was
combined with 5 µL of 5X loading dye (250 mM Tris-HCl pH 6.8, 10% SDS, 30% glycerol, 5%
β-Mercaptoethanol, 0.02% Bromophenol Blue) and heated at 95 °C for 5 minutes. Samples were
then centrifugated briefly and then added to separate with a protein MW standard ladder (GoldBio
#P007-500) lanes in a 1.5 cm 5% acrylamide stacking gel on top of a 12% acrylamide Tris-SDS
separating gel submerged in SDS-PAGE running buffer (25 mM Tris-Base pH 7.6, 200 mM
Glycine, 1% SDS). Loaded gels were run at 150 V for 60 minutes or until dye had reached the end
of the gel.
When SDS-PAGE gels had finished running, the gel was removed, rinsed with distilled
water, and placed on a nitrocellulose membrane, and sandwiched between two pieces of filter
paper and two sponges in a western blot cassette submerged in chilled transfer buffer (25 mM TrisBase pH 7.6, 200 mM Glycine, 20% methanol). The western blot cassette was placed in a transfer
tank filled with transfer buffer and chilled with ice. The protein was transferred from the gel to the
nitrocellulose membrane at 0.25 Amps (constant current) for 90 minutes.
When the transfer was complete, membranes were removed, rinsed with TBS buffer (10
mM Tris-Base pH 7.6, 150 mM NaCl), and then dried for 15 minutes. Once dried, the membranes
were rehydrated with distilled water and blocked in 5 mL of blocking buffer (10 mM Tris-Base
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pH 7.6, 150 mM NaCl, 5% powdered milk, 0.1% tween-20) shaking for 1 hour. At the end of 1
hour, 5 µL of anti-Heme Oxygenase-1 (Cell Signaling Rabbit pAB #70081) and 5 µL of anti-βactin (Cell Signaling Mouse mAB #3700) were added to the blocking solution and incubated at 4
°C shaking overnight. The next day the antibody solution was removed, and the blot was washed
3x for five minutes with TBS-T (10 mM Tris-Base pH 7.6, 150 mM NaCl, 0.1% tween-20). After
washes, 5 mL of blocking buffer with 1 µL of anti-rabbit (Licor Donkey #926-32213 800 nm
fluorescence) and 1 µL of anti-mouse (Licor Donkey #926-68072 680 nm fluorescence) secondary
antibodies conjugated to fluorescent probes was added to the blots to incubate for 1 hour. At the
end of one hour, antibodies were removed, and the blots were rinsed three times with TBS buffer.

Western Blot Data Analysis
Blots were imaged on the LI-COR Odyssey® CLx scanner scanning for fluorescence at
680 nm and 800 nm. Images were processed and quantified using ImageStudio™ Lite software.
Pixel intensity was calculated for bands of interest. One single Heme Oxygenase-1 band at 34.6
kDa was quantified for each lane on the 800 nm channel, and a single β-actin band at 42 kDa was
quantified on the 680 nm channel in each lane. To normalize samples, the HO-1 intensity was
divided by the β-actin intensity for every lane. For replicates across gels, each normalized intensity
was divided by the normalized intensity of the wildtype negative control. Averages and standard
deviations were calculated for each sample across replicates. One-tailed heteroscedastic T-tests
were calculated against the wildtype negative control sample. P-values less than 0.05 were
considered significant.
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Results
Effect of Gold Nanocrystals on Nrf2 Induction
We hypothesized that the larger (13-15 nm) gold nanocrystals would have a similar effect
as the 3-5 nm spherical gold nanoparticles tested by Lai et al.64 We incubated HepG2 cells with
various concentrations of the gold nanocrystals and western blotted for heme oxygenase-1 (HO1), which Nrf2 upregulates to test this hypothesis. The results from these blots are shown below in
figure 14. In these experiments, we used three different Nrf2 activators as a positive control,
Sulforaphane (SFN), 2-Trifluoromethyl-2'-methoxychalcone (2T2M), and 3H-1,2-Dithiole-3thione (D3T). During a 6-hour induction, the best and most consistent activator was 2T2M, and
those results are shown in 14a. None of the gold nanocrystal treatments ranging from 0.01 to 2
ppm in concentration affected HO-1 levels during that 6 hours. To be sure of this we tested the
same concentrations of the gold nanocrystals during a 12-hour induction to make sure that it was
not a slow induction of Nrf2. However, even during the 12-hour induction, we observed no changes
in HO-1 levels (figure 14B).

Figure 14: Induction of Heme Oxygenase-1 with Gold Nanocrystals. HepG2 cells were treated with known inducers of Nrf2 or
varying concentrations of gold nanocrystals, and the amount of HO-1 was measured as a readout of activation. A-B shows western
blots and quantifications. Yellow graphs indicate that three replicates were used. * p-value <0.05. A: 6-hour induction of HepG2
cells with controls and gold nanocrystals. B: 12-hour induction of HepG2 cells with control and gold nanocrystals..
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Discussion
Our experiments show that physiologically relevant levels of the gold nanocrystals (around
1 ppm) are not sufficient to stimulate the Nrf2 pathway to produce HO-1. This was a surprising
finding since similar gold nanoparticles have previously shown to be excellent activators of Nrf2.64
A shortcoming in our experiment was that we didn’t have access to the same gold nanoparticles
tested by Lai et al. to be used as a positive control. It would have been good to see if our
experimental conditions were sufficient to confirm their results and validate our own.
One key difference between the nanoparticles tested by Lai et al. and the gold nanocrystals
we used is size. Their nanoparticles were 3-5 nm in diameter while the gold nanocrystals we used
have a diameter around 15 nm in diameter. Previous studies have found that small gold
nanoparticles 1.4-1.5 nm in diameter to be toxic in vitro and some animal models.66–68 While it has
been shown that 5 nm gold nanoparticles are relatively safe68 it is possible that the smaller-sized
nanoparticles are more catalytic, or that a greater concentration can enter cells and interact on
molecular scales. It is possible that as nanoparticles get larger, their ability to interact with cells on
a molecular level is slowly lost. This could explain why the 5 nm gold nanoparticles were able to
activate Nrf2 and the gold nanocrystals were not.
In the future, it would be interesting to observe the activation of Nrf2 with a wide array of
gold nanoparticles and nanocrystals differing in size and shape. There could be interesting treads
in Nrf2 activation related to size and shape. Given more time, I would like to perform an extensive
characterization of all different sizes and shapes of nanoparticles to determine what factors make
them good activators of Nrf2.
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CHAPTER 5: Isolation and Identification of the Protein Corona of Gold Nanocrystals
Introduction
Knowing any drug's direct interactors is essential to understanding its mechanism. This is
especially true for nanoparticles due to what is known by those in material science as
‘biofouling’.69 When nanoparticles are placed in biological solutions, a protein ‘corona’
spontaneously forms on the nanoparticle's surface. This protein corona affects cellular
internalization, covers up catalytic surfaces, and determines the nanoparticle's biological
identity.70–72 Learning the identity and dynamics of a nanoparticle's protein corona is essential to
understanding how it will function in vivo. To our knowledge, a protein corona has not been
characterized for gold nanocrystals.
The protein corona is known to be dynamic, with different coronas being formed in
different tissues and settings.35 Understanding the protein corona of gold nanocrystals in different
tissues would allow us to see what proteins are near the nanocrystal’s catalytic surface and generate
a new hypothesis about their mode of action. Additionally, understanding the protein corona of
gold nanocrystals could help us understand their disposition while traveling through a living
organism and potential cell types with which it may preferentially interact. This may be especially
important since it is known that the protein corona sometimes disguises nanoparticles so they can
gain entry into specific cell types.73
Our work in this chapter characterizes a method for isolating the protein corona from gold
nanocrystals in a way that can directly prepare the protein samples for mass spectrometry and
proteomic analysis. It also offers a preliminary characterization of the protein corona of gold
nanocrystals in fetal bovine serum (FBS).
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Experimental
Setup and Controls
The protocol for isolating the gold nanocrystal’s protein corona was inspired by several
other papers that performed proteomic analysis on the protein corona of other nanoparticles.74–78
One key difference between the protocols in these papers and the protocol presented here is that
we did not use an SDS-PAGE gel to separate proteins prior to LC-MS2. Instead, by using guanidine
HCl and TCEP as elution agents, we were able to feed our protocol for isolating the protein corona
to a spin-filter proteomic mass spec prep protocol adapted from Wis´niewski et al.79 This protocol
allowed us to prepare the protein corona for mass spectrometry using well-known methods without
having to perform any complex buffer exchanges.
The gold nanocrystal’s FBS protein corona was formed and isolated by incubating the
nanoparticles in FBS and then isolating the nanoparticle with its protein corona by centrifuging
and removing the supernatant. The nanocrystal-PC complex was then washed by resuspending it
in PBS, centrifuging, and removing the supernatant. This washing process was repeated three
times. After the last centrifugation, the nanocrystals were resuspended in a reducing and denaturing
agent that would reduce any gold thiol bonds and remove non-specific protein-gold interaction.
This solution was heated to assist in the denaturation. After causing the protein corona and the
gold nanocrystals to dissociate, the nanoparticles were separated from the solution by
centrifugation. The supernatant was removed and its protein content quantified. These samples
were then trypsin digested and prepared for mass spec. When ready, samples were run on LC-MS2
on an Orbitrap mass spectrometer. Peak assignments were made using PEAKS mass spec software.
This process is shown in figure 15.
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For every FBS-gold nanocrystal sample run, a no-gold-control was also included. This nogold-control was a sample identical to the FBS- gold nanocrystal, but with no nanocrystals, only
FBS was included. These controls were treated the same as the nanocrystal samples and run using
LC-MS2 as well. These no-gold-controls allowed us to control for our washing steps and provide
a baseline from which we could calculate fold change from control to an actual sample.

Figure 15: Experimental Workflow to Isolate and Analyze the Protein Corona of Gold Nanocrystals. Gold nanocrystals are
incubated with a biological fluid allowing a protein corona to form. This nanoparticle-corona complex is isolated via centrifugation
and washed to remove excess protein. Once washed, the protein corona is isolated from the gold by addition of denaturing and
reducing agents. The isolated protein corona is then digested and analyzed using LC-MS2. PEAKS software is used to make peptide
assignments from which fold changes and statistical significance can be calculated.

Forming and Isolating an FBS Protein Corona on Gold Nanocrystals
1.6 mL of 500 ppm gold nanocrystals was incubated with 0.4 mL of FBS (Corning #35010-CV) in three 15 mL conical vials. For the no-gold-controls, 1.6 mL of 6 mM sodium
bicarbonate (the vehicle of the gold nanocrystals) was combined with 0.4 mL of FBS in three 15
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mL conical vials. Both samples and controls were incubated in a 37 °C water bath for 1.5 hours to
encourage protein corona formation. After incubation, samples were centrifugated at 20,000 G for
1 hour at 4 °C (to maintain protein corona interactions). The FBS supernatant was carefully
removed using a pipette and leaving only a small layer of liquid over the nanoparticle pellet. For
the no gold control, approximately 20 µL of liquid was left at the bottom of the tube. Each sample
was then resuspended in 1 mL of 7 mM sodium bicarbonate, mixed well, and then centrifugated
at 20,000 G for 1 hour. The addition of sodium bicarbonate, centrifugation, and subsequent
removal of supernatant was repeated a total of three times. After the last centrifugation, the wash
supernatant was removed and the samples were resuspended in 200 µL of 6M Guanidine-HCl, 100
mM Tris-HCl pH 8.5, 50 mM tris(2-carboxyethyl)phosphine (TCEP). Once resuspended, samples
and controls were heated to 90 °C for 30 minutes. At the end of 30 minutes, the samples and
controls were centrifugated at 20,000 G for 1 hour at 25 °C. When finished the supernatant was
removed taking care not to disturb the gold pellet. This supernatant was used in further analysis.

Protein Quantification and Preparation for Mass Spectrometry
The amount of protein in each supernatant was determined using a 96-well Bradford assay
(Sigma Aldrich #B6916). After protein quantification 200 mM chloroacetamide (CAM) was added
to each sample so that the final CAM concentration was 40 mM; this solution was heated at 90 °C
for 10 minutes. At this point, each of the three replicates was combined together (gold nanocrystal
PC with gold nanocrystals PC, no-gold-control with no-gold control) to obtain enough protein for
mass spectrometric analysis.
The combined sample and the combined control were added to a 30,000 kDa molecular
weight cutoff spin filter and spun at 14,000 G for 20 minutes, after which the flow-through was
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discarded. These filters were washed two times with 6 M Guanidine HCl, and three times with
mass spec wash buffer (5 mM ammonium bicarbonate pH 8, 10% v/v acetonitrile), each time
spinning the samples at 14,000 G for 10 minutes and discarding the flow-through. After these
washes, the sample was resuspended to 1 µg/µL protein concentration in mass spec wash buffer,
the control was resuspended in the same volume as the sample. Trypsin protease (New England
Biolabs #P8101S) was added to a 1:50 trypsin:protein ratio and left to shake overnight at 37 °C.
At the end of this incubation period, phenylmethylsulfonyl fluoride (PMSF) was added to a final
concentration of 1 mM to stop the trypsin digest. This digested solution was spun on its spin filter
at 14,000 G for 20 minutes, the filtrate was collected and put in a mass spec vial, the filter was
washed with 100 µL mass spec wash buffer and centrifugated as before, this filtrate was added to
the original flow through in the mass spec vial. All samples were dehydrated for 2 hours on a
SpeedVac system and stored in the -80 °C freezer.

Liquid Chromatography and Mass Spectrometry
Only one gold nanocrystal protein corona replicate and one no-gold-control replicate were
submitted for mass spectrometry. Samples were run by the Fritz B. Burns Biological Mass
spectrometry facility. Both samples were resuspended in mass spec buffer A (0.1% formic acid in
optima water) to 1 µg/µL for the gold nanocrystal PC sample, the same volume was used to
resuspend the control. 6 µL of both the sample and control were injected on an EASY-nLC liquid
chromatography (LC) unit (Thermo Fisher) online with an Orbitrap Fusion Lumos Tribrid Mass
Spectrometer (Thermo Fisher). A rapid separation LC (RSLC) column (EASY-spray column
pepMap ® RSLC, C18, 2 μM, 100 Å, 75 μM × 15 cm) was used to separate peptides. Mass spec
buffers A (0.1% formic acid in optima water) and B (optima water and 0.1% formic acid in 80%
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acetonitrile) served as the mobile phase for LC. The peptides were eluted at 300 nL/min with the
following gradients over 2 h: 5–22% B for 85 min; 22–32% B for 15 min; 32–95% B for 10 min;
and 95% for 10 min. Nano-spray ionization was used to introduce ions to the Orbitrap.
Peptide sequence data was acquired using 3-second scan cycles in data dependent
acquisition (DDA) mode. The Orbitrap resolution was set to 120,000 with a scan range between
375 and 1700 m/z. The intensity threshold was set to 5e3 with a maximum injection time of 50
ms. Peptides with charge states of 2–6 were selected from the top abundant peaks by the
quadrupole for high-energy collisional dissociation (HCD with normalized energy 30, activation
time 10 ms) MS/MS, and the fragment ions were detected in the linear ion trap with target AGC
value of 1e4 and a dynamic maximum injection time. The dynamic exclusion time was set at 60 s.
Precursor ions with ambiguous charge states were not fragmented.

Data Analysis
PEAKS software (version 8.5) was used to make peak assignments on the mass spec data
for further quantification. The Swiss-Prot Bos taurus database was used to search the mass spectra
and make assignments based on homology matches. In brief, the variables for the search were:
fixed carbamidomethylation and variable methionine oxidation/pyroglutamate from glutamine,
fragment ion tolerance: 0.5, max number of PTM’s: 3, de novo score(%) threshold: 15, peptide hit
threshold: (-10logP): 30.
Once peaks had been assigned the top 118 proteins found in the gold nanocrystal’s protein
corona but not in the no-gold-control were submitted to the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) online server against a Bos taurus background.
These 118 proteins were classified using COG Ontology, Up Keywords, Up Seq Feature, GoTerm
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BP Direct, GoTerm CC Direct, GoTerm MF Direct, KEGG Pathway, InterPro, PIR Superfamily,
and Smart annotation lists. These were used to create functional annotation clustering under high
stringency from the 118 proteins submitted from which the top three clusterings were reported in
the results section.

SDS-PAGE Analysis of the Protein Corona Isolation
A separate experimental set of gold nanocrystals and the no-gold-control were incubated
and isolated as before, only 200 µL of 5X loading dye (250 mM Tris-HCl pH 6.8, 10% SDS, 30%
glycerol, 5% β-Mercaptoethanol, 0.02% Bromophenol Blue) was added to elute the protein corona
from the nanoparticles while being heated at 90 °C for 30 minutes. In addition to the final elution
from the gold nanocrystals and the no-gold-control, 50 µL samples were taken from the original
FBS supernatant and each of the washes to assess isolation efficiency. To each of these additional
samples, 5 µL of 5x loading dye was added and samples were heated at 90 °C for 10 minutes. All
samples were then centrifugated briefly and 50 µL were added with a protein MW standard ladder
(GoldBio #P007-500) to separate lanes in a 1.5 cm 5% acrylamide stacking gel on top of a 12%
acrylamide Tris-SDS separating gel submerged in SDS-PAGE running buffer (25 mM Tris-Base
pH 7.6, 200 mM Glycine, 1% SDS). Loaded gels were run at 150 V for 60 minutes or until dye
had reached the end of the gel.
When SDS-PAGE gels had finished running, the gel was removed, rinsed with distilled,
water, and then soaked in destain buffer 1 (50% methanol and 10% glacial acetic acid) for 30
minutes to fix the gel. This buffer was removed and Coomassie blue stain (0.1% Coomassie
Brilliant Blue R-250, 50% methanol, and 10% glacial acetic acid) was added, microwaved on high
for 15 seconds, then allowed to stain for 30 minutes. Coomassie stain was then removed, the gel
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was rinsed with water, destain buffer 1 was added, and the gel was microwaved on high for 15
seconds. Destain buffer 1 was immediately discarded, and destain buffer 2 (40% methanol and
10% glacial acetic acid) was added to the gel and microwaved for 15 seconds. This mixture was
allowed to shake overnight with a Kimwipe until gel had destained and bands were visible. Gels
were imaged on the LI-COR Odyssey® CLx scanner scanning at 680 nm and 800 nm. Images
were processed using ImageStudio™ Lite software.

Lowry Analysis of Protein Corona Isolation
To confirm the efficiency of protein corona isolation, a protein quantification based on the
technique by Lowry et al.45 was performed in triplicate on the FBS supernatant, the ammonium
bicarbonate washes, and elution that had been washed with mass spec wash buffer from the gold
nanocrystals protein corona isolation. Twelve bovine serum albumin (BSA) standards between 0
and 55 µg/mL were used to quantify the sample. One-tailed heteroscedastic T-tests were calculated
for the absorbance at 750 nm between the 0 µg negative control and all other samples. P-values
less than 0.05 were considered significant.

Results
Isolation of the Gold Nanocrystal FBS Protein Corona
To confirm our ability to isolate the protein corona from gold nanocrystals, we ran samples
from the original FBS supernatant, the wash steps, and the final elution of the protein corona on
an SDS-PAGE acrylamide gel and stained for total protein using Coomassie blue. We repeated
this process on the no-gold-control as well. The resulting SDS-PAGE gels are shown in figure
16A-B. In both gels, many intense protein bands are evident in the FBS supernatant lane with the

49

highest abundance protein between 63 and 75 kDa (bovine serum albumin MW=66kDa). All
protein bands decreased in intensity for each wash lane until only a faint band was observed above
63 kDa (most likely BSA) in wash four. In figure 16A, the no-gold-control elutions show only
faint bands around 63 kDa. In figure 16B, the gold nanocrystal protein corona elutions show a very
specific banding pattern. These figures together show that while not perfect, our isolation seems
to work very effectively to obtain the protein corona.
To add additional evidence to our ability to isolate the gold nanocrystal’s protein corona
we use a Lowry assay to quantify the protein in each of the purification steps from the same

Figure 16: Isolation of the Protein Corona of Gold Nanocrystals in FBS. The gold nanocrystal’s FBS protein
corona was isolated by centrifugation and 4 PBS washes. Guanidine-HCl and TCEP were used to remove the
protein corona. A: SDS-PAGE gel stained with Coomassie blue of no gold control washes and elutions,
almost no protein is seen in these elutions. B: SDS-PAGE gel stained with Coomassie blue of gold nanocrystal
washes and elutions, a very specific protein pattern is seen in the elutions of the protein corona. MW BSA
=66 kDa. C: Lowry assay showing the quantification of protein in each of the washes and elution of the gold
nanocrystal protein corona. Green bars were significantly different (p-value<0.05) than the 0 baseline, while
red bars were not significantly different (p-value>0.05)
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purification in triplicate and calculated statistical significance between samples. These results are
shown in figure 16C. Decreased total levels of protein are observed until wash 3 when the
absorbance readout is statistically indistinguishable from the negative control. The elution then
appears to shoot back up and is statistically different from the zero-baseline showing that our
elution strategy is effective.

Mass Spectrometry and Proteomic Analysis
Due to time and reagent constraints, only one gold nanocrystal protein corona replicate and
one no-gold-control replicate were submitted for LC-MS2. Because of this, no statistical
significance could be calculated for the resulting data. That being said, I chose to analyze and
present this data as a preliminary set of results. This data may not be accurate because no statistical
significance was calculated, but it may serve as a starting point for additional studies probing the
protein corona of gold nanocrystals.
The mass spec results indicated that 445 proteins had been identified in the gold
nanocrystal’s protein corona and 352 had been identified in the no-gold-control. Of those proteins
identified, 118 were unique to the gold nanocrystal protein corona, 25 were unique to the no-goldcontrol, and 327 were shared between the two groups (figure 17A). Because I couldn’t calculate
statistical significance, I chose to only analyze the 118 unique proteins found in the gold
nanocrystal’s protein corona. I submitted these proteins to the Database for Annotation,
Visualization, and Integrated Discovery (DAVID) online to classify the proteins into functional
groups and determine what commonalities they may have (figure 17B). Under a high stringency
classification, three clusters were made with an enrichment score above two. The top cluster with
an enrichment score of 5.56 included secreted signaling peptides rich in disulfide bonds. The
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second cluster had an enrichment score of 2.97 and included EF-hand calcium-binding proteins.
The third cluster had an enrichment score of 2.24 and was comprised of cysteine proteases. Both
cluster 1 and cluster 3 include proteins rich in cysteine thiol groups which are known to form
covalent bonds to gold surfaces. These could prove to be real interactions that will need to be
monitored in future experiments. Cluster 2 consisted of proteins containing a calcium-binding EF-

Figure 17: Data Analysis of 1 Replicate of the Gold Nanocrystal PC and No Gold Control. A: PEAKS analysis
of mass spectrometry data identified 445 proteins in the gold nanocrystal PC and 352 proteins in the no gold
control. 118 proteins were identified in the gold nanocrystal PC that were not found in the no gold control.
B: Those 118 proteins were submitted to the Database for Annotation, Visualization, and Integrated
Discovery (DAVID), searching for significant clustering patterns against a Bos taurus background. The top
three clusters obtained after being searched with high stringency are shown in this table. Cluster 1 included
secreted signaling peptides rich in disulfide bonds. Cluster 2 included EF-hand calcium binding domains.
Cluster 3 included cysteine proteases.
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hand domain, it is possible that this domain that binds to calcium ions also interacts with a surface
composed of gold ions.

Discussion
In this chapter, we confirmed that we can successfully purify and isolate the protein corona
of gold nanocrystals. We also obtained preliminary mass spectrometry results of gold nanocrystal’s
protein corona in FBS, which serves as a model of human serum. Unfortunately, due to limitations
in time and reagents, we were only able to characterize one replicate of this protein corona and its
control. Because of that, the results obtained could not be analyzed statistically making it difficult
to determine which proteins were really present in the protein corona but not in the no-gold-control.
Due to this fact, these results cannot be used as a final conclusion as to the composition of the gold
nanocrystal’s protein corona, but they can be used as a preliminary list from which to pursue future
experiments.
These preliminary results identified 118 proteins bound uniquely to the gold nanocrystals
while 327 were also found in the no-gold-control. It would be good to increase the number of
washes during purification to reduce the number of proteins being identified in the no-gold-control
and find out if some of these 327 proteins are also specific to the gold nanocrystal’s protein corona.
The results from DAVID clustering indicate that some cysteine and EF-hand containing
proteins from FBS tend to associate with gold nanocrystals and form the protein corona. These
results were searched against a general Bos taurus background. A better background would be the
serum proteome from FBS that could distinguish how enriched these proteins are specifically in
serum. Running an FBS control sample on LC-MS2 to serve as a background will be a necessary
addition to our experimental methods to obtain stronger results. In the future, it would also be very
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interesting to not only replicate these results but also to see if this same type of clustering appears
in the gold nanocrystal’s protein corona in different biological settings, such as in liver or nerve
cells.
Future studies could pursue the identity of the gold nanocrystal’s protein corona in neurons
and oligodendrocytes to determine how the protein corona could be affecting a nanocrystals ability
to treat neurodegenerative disease. Another interesting study that could be pursued would be to
form a serum corona around the gold nanocrystals and use those to treat neural cells. An analysis
of the resulting protein corona (serum+neural) would give a picture of how much the serum corona
remains on the nanocrystals after entering a new biological environment (the neuron). Yet another
study that could be performed would be to test gold nanocrystal’s catalytic efficiency to oxidize
NADH to NAD+ (modeling the experiment done by Robinson et al.)31 with different protein
coronas to determine under what setting the gold nanocrystals displays optimal catalytic activity.
Although this study remains incomplete, the promise of new insights into the mechanism
of gold nanocrystals makes the study of its protein corona very promising. The work in this chapter
provides a framework by which future protein corona proteomic experiments can be pursued, not
only on the gold nanocrystals we tested, but also on other nanoparticles.
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